Kombiglyze XR available for type 2 diabetes

Kombiglyze XR approved for treatment of type 2 diabetes mellitus (DM)
Kombiglyze XR approved for treatment of type 2 diabetes mellitus (DM)
Bristol-Myers Squibb and AstraZeneca announced that Kombiglyze XR (saxagliptin and metformin HCl extended-release) is now available for the treatment of type 2 diabetes as an adjunct to diet and exercise when treatment with both saxagliptin and metformin is appropriate. Kombiglyze XR is available in 5/500mg, 2.5/1000mg, and 5/1000mg dosage strength tablets.

 For more information call (800) 721-5072 or visit www.bms.com or www.astrazeneca-us.com.